Assessment Of Spanlastic Vesicles Of Zolmitriptan For Treating Migraine In Rats

Abstract

Objective

To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%).

Materials and methods

A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally.

Results

We found decreased T_max, increased C_max, AUC_0–6, AUC_{0–∞ and} ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan.

Conclusion

Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment.

Keywords:

• zolmitriptan
• Zol
• intranasal delivery
• brain targeting
• spanlastics
• SLs
• pharmacokinetics
• pharmacodynamics
• migraine

Disclosure

The authors declare that they have no competing interests in this work.